This is the comparison everyone searching for GLP-1 information wants answered. Semaglutide and tirzepatide are the two dominant GLP-1 medications on the market, and they work differently at a molecular level. One isn't simply "newer" or "stronger" — they target different receptor pathways, produce different outcomes, and come with different trade-offs.
We break this down across five dimensions: mechanism, efficacy, side effects, pricing, and access. Then we give you a clear verdict.
How They Work: One Receptor vs. Two
Semaglutide (brand names: Wegovy for weight loss, Ozempic for diabetes) is a GLP-1 receptor agonist. It mimics the GLP-1 hormone your gut naturally produces after eating, which slows gastric emptying, reduces appetite, and improves insulin sensitivity. One mechanism, executed exceptionally well.
Tirzepatide (brand names: Zepbound for weight loss, Mounjaro for diabetes) is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The dual mechanism appears to produce greater metabolic effects and more weight loss than GLP-1 activation alone.
Weight Loss: The Head-to-Head Data
This isn't speculation — there's now a direct head-to-head trial. The SURMOUNT-5 study, published in the New England Journal of Medicine in 2025, compared tirzepatide directly against semaglutide in the same patient population.
| Metric | Semaglutide (Wegovy 2.4mg) | Tirzepatide (Zepbound 15mg) |
|---|---|---|
| Avg. weight loss | 13.7% | 20.2% ✓ |
| Source trial | SURMOUNT-5 | SURMOUNT-5 |
| Relative difference | Tirzepatide produced 47% greater weight loss | |
| Best standalone trial | ~15% (STEP 1, 68 wks) | ~22.5% (SURMOUNT-1, 72 wks) |
| Oral option | ~16.6% (OASIS 4, oral Wegovy) | Orforglipron pending approval |
The numbers are clear: tirzepatide produces meaningfully more weight loss. A 47% relative improvement is not a marginal difference — for a 220-pound person, that's roughly the difference between losing 30 pounds vs. 44 pounds.
Side Effects: Similar Profile, Slight Differences
Both medications share the same primary side effects because they both activate GLP-1 receptors. The gastrointestinal effects — nausea, diarrhea, vomiting, constipation — are the most common for both and typically improve over time as your body adjusts during dose titration.
| Side Effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | Common (most reported) | Common (most reported) |
| Diarrhea | Common | Common |
| Constipation | Common | Common |
| Vomiting | Moderate | Moderate |
| Injection site reactions | Mild | Mild |
| Heart rate increase | Small increase noted | Less pronounced |
Both carry the same FDA boxed warning about medullary thyroid carcinoma risk (based on rodent studies) and the same contraindications: personal or family history of MTC, MEN2 syndrome, and pregnancy. Neither medication has a dramatically worse side-effect profile than the other — the main differentiator remains efficacy and cost.
Pricing: Where It Gets Complicated
Pricing depends entirely on whether you're paying out of pocket, using insurance, or going the compounded route.
Brand-Name Self-Pay
| Source | Semaglutide | Tirzepatide |
|---|---|---|
| List price | Wegovy ~$1,349/mo | Zepbound ~$1,080/mo |
| Manufacturer self-pay | NovoCare: $199-$499/mo | LillyDirect: $299-$449/mo |
| Oral option | Oral Wegovy: $149-$299/mo | Not yet available |
| With savings card | As low as $25/mo (insured) | As low as $25/mo (insured) |
Compounded
| Provider | Compounded Semaglutide | Compounded Tirzepatide |
|---|---|---|
| Typical range | $150–$300/mo | $200–$400/mo |
| Availability | Restricted (shortage ended Feb 2025, FDA enforcing) | More available (different regulatory status) |
Insurance and Access: Semaglutide's Big Advantage
This is where semaglutide pulls ahead for many patients. Wegovy has an FDA-approved cardiovascular indication — it's approved for cardiovascular risk reduction in adults with established heart disease and overweight/obesity. This means Medicare Part D can cover Wegovy under a cardiovascular diagnosis code, right now, through standard formulary channels.
Zepbound has an FDA-approved indication for obstructive sleep apnea, which opens some insurance doors but isn't as broadly applicable as cardiovascular disease in the Medicare population.
Both medications will be available through the Medicare GLP-1 Bridge program starting July 2026 at a $50/month copay, and both have manufacturer savings cards for commercially insured patients. But for patients who need coverage today, semaglutide's cardiovascular pathway is a meaningful advantage.
The Verdict: It Depends on What You Prioritize
Choose tirzepatide (Zepbound) if: Maximum weight loss is your top priority. You can afford brand-name pricing or have insurance that covers it. You want the dual-mechanism approach that produced 20%+ average weight loss in trials.
Choose semaglutide (Wegovy) if: You need more access pathways — especially if you're on Medicare with cardiovascular disease. You want the oral pill option (oral Wegovy, starting at $149/mo via NovoCare). You prefer the medication with the longest safety track record in humans.
Either way: Both medications produce clinically significant weight loss far beyond anything previously available. The "wrong" choice between these two is still a dramatically effective treatment. The best GLP-1 is the one you can actually access, afford, and stay on long-term.
Ready to Compare Providers?
See real pricing from verified GLP-1 providers offering both semaglutide and tirzepatide.
Compare Providers →